Publication Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

New Developments in Targeted Therapy for Gastrointestinal Stromal Tumors
Oncology Briefings Vol. 7, No. 1

This activity is not sanctioned by, nor a part of, the 2009 Gastrointestinal Cancers Symposium.

0.5 AMA PRA Category 1 Credit(s)™
Release Date: March 31, 2009
Expiration Date: March 31, 2010

Publication Overview

Authors

Medical writer: Timothy Quill, PhD; Reviewed by: Jean-Yves Blay, MD, PhD

Overview and Purpose

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor type of the gastrointestinal tract; approximately 6000 new cases are diagnosed in the United States each year. Activating mutations in the c-Kit receptor tyrosine kinase (TK) are the predominant cause of GIST, and the integration of TK-targeted agents into GIST treatment has markedly changed the management of these tumors. The use of TK inhibitors (TKIs) as therapy for GIST continues to evolve from treatment for metastatic disease to adjuvant therapy following surgical resection. Data on mutation status and efficacy that are relevant to the planning of an optimal personalized treatment course are emerging. Other novel agents under investigation are also expanding treatment options for patients with GIST.

The purpose of this activity is to inform physicians of new developments in the use of targeted therapies in patients with both resectable and unresectable GIST.

Target Audience

This activity is intended for medical oncologists involved in the care of patients with gastrointestinal stromal tumors (GIST). No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Evaluate the efficacy and safety of TKIs in the adjuvant setting for patients with high-risk resectable GIST
  • Discuss the impact of specific mutations in c-Kit on the efficacy of treatment with small-molecule TKIs
  • Assess the treatment options for patients with metastatic GIST following progression on initial therapy with a TKI

Instructions for Participation

This online activity provides a maximum of 0.5 AMA PRA Category 1 Credit™.

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. Study the educational activity.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

CME credit will be granted for only 1 form of participation, either online or via the printed publication.

Complete the test(s) and evaluation by March 31, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

 
Timothy Quill, PhD
No relevant relationships to disclose
 
Jean-Yves Blay, MD, PhD
Research Funding – GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., Roche Pharmaceuticals
Paid Consultant – ARIAD Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Pharmaceuticals
Speaker's Bureau – Novartis Pharmaceuticals Corporation, Pfizer Inc.
 
PER Editorial Staff
No relevant relationships to disclose
 
This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this online newsletter for FDA-approved dosing, indications, and warnings.
 
Commercial Support
An educational grant for this activity was provided by Novartis Oncology.
 
Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.
 
If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.
 
PC Users
If you need to upgrade your Web browser, follow one of the links listed below:
Macintosh Users Compatible Web browsers include Firefox (Outside Source) and Apple Safari (Outside Source)
 
Disclaimer
The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.
 
Please consult full prescribing information for any drugs or procedures discussed within.
 
Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949–0045.
 
All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
 
©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
 
All correspondence should be directed to:
Editor, New Developments in Targeted Therapy for Gastrointestinal Stromal Tumors
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367–3400
Fax: (214) 367–3304
E–mail: editor@cancerlearning.com

Download a Print Version of this Publication*

*Print format is for reference only

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology